Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Neutral 77.3%

Neg 0% Neu 77.3% Pos 0%

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and lowers the price target from $21 to $18.